MedPath

Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

Phase 2
Completed
Conditions
Multiple Myeloma
Registration Number
NCT00193557
Lead Sponsor
SCRI Development Innovations, LLC
Brief Summary

This phase I study will evaluate the feasibility and toxicity of weekly bortezomib in the treatment of relapsed or refractory multiple Myeloma and determine whether a twice-weekly schedule of bortezomib is effective in producing responses in patients with stable disease or progression after weekly bortezomib

Detailed Description

Upon determination of eligibility, patients will be receive:

* Bortezomib

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria

To be included in this study, you must meet the following criteria:

  • Multiple Myeloma
  • Received no more than 2 previous treatment regimens for multiple Myeloma
  • ECOG performance status 0, 1, or 2
  • Serum creatinine < 2.0mg/dL
  • calculated or measured creatinine clearance > 30ml/minute
  • Measurable or evaluable disease
  • Provide written informed consent prior to receiving protocol therapy.
Exclusion Criteria

You cannot participate in this study if any of the following apply to you:

  • Moderate or severe peripheral neuropathy
  • Other serious medical conditions
  • Other active malignancies
  • history of treatment for other invasive cancers
  • Women who are pregnant or lactating

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
objective response rate
Secondary Outcome Measures
NameTimeMethod
overall survival
Safety
progression-free survival

Trial Locations

Locations (2)

Tennessee Oncology, PLLC

🇺🇸

Nashville, Tennessee, United States

Florida Cancer Specialists

🇺🇸

Fort Myers, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath